ABBV
The deal hangover
AbbVie says it’s trimming its full-year guidance to reflect the pending Apogee Therapeutics acquisition. Translation: the company is paying for growth now, and that bill is showing up on the earnings forecast.
Why this matters
Guidance cuts are never exactly a vibe, even when there’s a strategic excuse attached. Investors tend to hear: “We like the future, but the present is getting a little more expensive.”
In AbbVie’s case, the market will be watching whether the Apogee deal adds enough long-term firepower to justify the short-term hit to earnings. Pharma investors are basically professional spreadsheet detectives, and this is the kind of line item they zoom in on with the intensity of a true crime podcast.
Big picture
The headline isn’t just that AbbVie bought something — it’s that the purchase is now affecting financial expectations. If management can show the acquisition helps fortify the portfolio and eventually boosts growth, the guidance cut may look like a speed bump. If not, it starts to feel like the kind of expensive detour investors hate.